Violeta Serra

Research interests

Publications

• High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

  Nature Communications · 2022 · https://doi.org/10.1038/s41467-022-32828-6

• INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors

  Cancer Discovery · 2021 · https://doi.org/10.1158/2159-8290.cd-20-1726

• ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.08.2102

• A decade of clinical development of PARP inhibitors in perspective

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz192

• A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

  EMBO Molecular Medicine · 2018 · https://doi.org/10.15252/emmm.201809172

• RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy099

• mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

  Nature · 2017 · https://doi.org/10.1038/nature22964

• Interrogating open issues in cancer precision medicine with patient-derived xenografts

  Nature reviews. Cancer · 2017 · https://doi.org/10.1038/nrc.2016.140

• Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

  Cancer Research · 2016 · https://doi.org/10.1158/0008-5472.can-15-0728

• A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds

  Cell · 2016 · https://doi.org/10.1016/j.cell.2016.08.041

• PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer

  Science Translational Medicine · 2015 · https://doi.org/10.1126/scitranslmed.aaa4442

• Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

  Molecular Cancer Therapeutics · 2014 · https://doi.org/10.1158/1535-7163.mct-13-0639

• Development of PI3K inhibitors: lessons learned from early clinical trials

  Nature Reviews Clinical Oncology · 2013 · https://doi.org/10.1038/nrclinonc.2013.10

• mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA -Mutant Breast Cancer

  Science Translational Medicine · 2013 · https://doi.org/10.1126/scitranslmed.3005747

• PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

  Cancer Discovery · 2012 · https://doi.org/10.1158/2159-8290.cd-11-0348

• AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

  Cancer Cell · 2011 · https://doi.org/10.1016/j.ccr.2010.10.031

• Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 + breast cancer patients

  Proceedings of the National Academy of Sciences · 2011 · https://doi.org/10.1073/pnas.1014835108

• PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

  Oncogene · 2011 · https://doi.org/10.1038/onc.2010.626

• NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

  Cancer Research · 2008 · https://doi.org/10.1158/0008-5472.can-08-1385

• Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

  Cancer Research · 2008 · https://doi.org/10.1158/0008-5472.can-08-1740

Current projects

No projects listed.